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Abstract. We have localized transforming growth 
factor-/~ (TGF-~) in many cells and tissues with im- 
munohistochemical methods, using two polyclonal an- 
tisera raised to different synthetic preparations of a 
peptide corresponding to the amino-terminal  30 amino 
acids of TGF-~.  These two antibodies give distinct 
staining patterns;  the staining by anti-CC(1-30)  is 
principally extracellular,  while that by anti-LC(1-30) 
is intracellular.  This differential staining pattern is 
consistently observed in several systems, including cul- 
tured tumor cells; mouse embryonic, neonatal,  and 
adult tissues; bovine fibropapillomas; and human co- 
Ion carcinomas.  The extracellular staining by anti- 
CC(1-30) partially resembles that seen with an anti- 
body to fibronectin,  suggesting  that extracellular TGF-~ 
may be bound to matrix proteins.  Tl~e intracellular 
staining by anti-LC(1-30)  is similar to that seen with 
two other antibodies raised to peptides corresponding 
to either amino acids 266-278 of the TGF-/~I precursor 
sequence or to amino acids 50-75 of mature TGF-/~I, 
suggesting that anti-LC(1-30)  stains sites of TGF-/~ 
synthesis.  Results from RIA and ELISAs indicate that 
anti-LC(1-30) and anti-CC(1-30)  recognize different 
epitopes of this peptide and of TGF-/~I itself. 
T 
RANSFORMING growth  factor-#  (TGF-/~),  ~ a  25-kD 
homodimeric peptide,  is a multifunctional  regulator 
of both cell growth and differentiation  and has been 
shown to influence extracellular matrix production by a num- 
ber of mechanisms  (for  reviews  see Roberts and  Sporn, 
1988;  Sporn  et  al.,  1987).  While  in  vitro  studies  have 
provided  valuable  information  concerning  the  nature  of 
TGF-/~ action, their relevance to in vivo systems is only be- 
ginning to be examined. To understand TGF-~ action in vivo, 
it is essential to be able to localize the protein in various tar- 
get tissues. 
As a  first approach to this problem,  we have developed 
antibodies against peptides corresponding to several regions 
of the TGF-~I  molecule for use in  immunohistochemical 
studies (Ellingsworth et al., 1986; Flanders et al., 1988). In 
this  article,  we present evidence  of two conformations  of 
TGF-/~I in several systems. When tissue sections are stained 
with two antibodies raised to different synthetic preparations 
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1. Abbreviation  used in this paper:  TGF-B, transforming growth factor-/~. 
of a peptide corresponding to the amino-terminal  30 amino 
acids of TGF-~, two distinct staining patterns are observed. 
One antibody stains principally  extracellular  TGF-B, while 
with the other,  staining  is intracellular. 
Since the two different antibody preparations  are now be- 
ing widely used, it is essential  to define the basis and con- 
sistency of their use as reagents  for staining.  In the present 
study, we have deliberately  examined a wide and diverse set 
of cells and tissues from three species of animals,  including 
normal embryonic and adult,  as well as malignant,  pheno- 
types. A consistent pattern of staining has been observed in 
all situations.  As shown in the following paper (Thompson 
et al.,  1989), combined use of the two antibodies  provides 
a useful tool for localizing TGF-B in many tissues of a given 
species. 
Materials and Methods 
Production of  Antisera 
All polyclonal antibodies to TGF-/~ were made in rabbits using synthetic 
peptides as immunogens. Anti-CC(l-30) was produced as described by EI- 
lingsworth et al. (1986) to a peptide corresponding  to the first 30 amino acids 
of mature TGF-~I  (Monsanto Co., St.  Louis, MO).  Anti-LC(1-30) was 
made to another synthetic preparation (Frederick Cancer Research Facility, 
Frederick, MD) of  the identical peptide. This second preparation of  the pep- 
tide was injected, also uncoupled, into New Zealand white rabbits as de- 
scribed (Flanders et al.,  1988).  Anti-P(50-75) was made to the peptide 
corresponding to amino acids 50-75 of mature TGF-~I, with an added car- 
©  The Rockefeller  University  Press, 0021-9525/89/02/653/8  $2.00 
The Journal  of Cell Biology,  Volume 108, February 1989 653-660  653 boxyl-terminal tyrosine (Peninsula Laboratories, Inc., Belmont, CA). This 
peptide was coupled to ovalbumin and injected as described (Flanders et al., 
1988).  Anti-pre(266-278) and anti-pre(46-56)  were made as described 
(Wakefield  et al.,  1988).  Rabbit anti-human fibronectin was from Col- 
laborative Research Inc. (Waltham, MA). 
Preparation of Cells and 1Issues  for Immunostaining 
Malignant cells from tissue cultures were trypsinized, resuspended in media 
containing 10% calf serum, washed three times with PBS, fixed overnight 
in 10%  neutral-buffered formalin, treated in Bouin's solution for 4-6 h at 
room temperature, and finally stored in 70% ethanol before embedding in 
paraffin and sectioning at 5 #m. Tumors arising in nude mice 5 wk after 
injection of cultured cells were fixed and sectioned in a similar manner, 
as  were  human  colon  carcinomas,  bovine fibropapillomas,  and  mouse 
embryos. 
lmmunohistochemical Staining 
TGF-~ was localized in sections as described by Heine et al. (1987),  using 
either avidin-biotin-peroxidase  or avidin-biotin-glucose oxidase kits (Vec- 
tor Laboratories Inc., Burlingame, CA). After deparaffinization, blocking 
of endogenous peroxidase in hydrogen peroxide/methanol, and permeabili- 
zation with hyaluronidase, the sections were blocked with 1.5 % normal goat 
serum/0.5% BSA, incubated overnight at 4°C with IgG fractions of anti- 
body prepared by protein A-Sepharose chromatography (Flanders et al., 
1988) at 25 tzg/ml, washed extensively, and then incubated with biotinylatexl 
goat anti-rabbit IgG and avidin-enzyme complex. Sections were stained 
with 3,Y-diaminobenzidine (Sigma Chemical Co.,  St.  Louis,  MO)  and 
hydrogen peroxide (for peroxidase), and with nitroblue tetrazolium and glu- 
cose (for glucose oxidase), and counterstained with either 1% methyl green 
or Giemsa, followed by May-Grunwald stain. 
Controls included (a)  replacing primary antibody with normal rabbit 
IgG,  (b) using antisera preincubated with TGF-~l-Sepharose resin to re- 
move TGF-/%specific antibodies (Heine et al., 1987), and (c) using primary 
antibody that had been preincubated with a 20-fold molar excess of the ap- 
propriate peptide for 2 h at room temperature before this mixture was ap- 
plied to the section. 
lmmunoassays 
RIAs and ELISAs were performed as described by Flanders et al. (1988). 
Antigens used in the ELISA assay included peptides corresponding to amino 
acids 1-10, 11-20, and 21-30 of TGF-~I (Peninsula Laboratories, Inc.); por- 
cine TGF-~2  (R &  D  Systems, Minneapolis, MN);  and TGF-~I purified 
from human platelets (Assoian et al.,  1983).  Western blotting of TGF-/31 
and 2 was carried out as described by Florini et al. (1986) and immune com- 
plexes were detected by an avidin-biotin conjugate immunoperoxidase kit 
(Vector Laboratories Inc.). 
Results 
Anti-CC(1-30) and Anti-LC(1-30) Give 
Different Patterns of lmmunohistochemical 
Localization of TG  F-/~ 
Two polyclonal antibodies (anti-CC[1-30]  and anti-LC[1- 
30]) were raised in rabbits against different synthetic prepa- 
rations (CC[1-30]  and LC[1-30]) of the same peptide se- 
quence, corresponding to the amino-terminal 30 amino acids 
of TGF-/31. Results presented here and by Ellingsworth et al. 
(1986) show that both antisera recognize TGF-/31 in a number 
of immunoassays. These two antisera were used to localize 
TGF-/3 in a variety of tissues. The staining pattern seen with 
anti-CC(1-30)  IgG  was  principally  extracellular  and  as- 
sociated with extracellular matrix, while the staining seen in 
many cell types with anti-LC(1-30) IgG was intracellular. 
An  example  of  the  two  staining  patterns  in  a  bovine 
fibropapilloma, as well as the specificity of the staining, is 
shown in Fig. 1 (A-D). Intracellular staining of  the papilloma 
epithelium by anti-LC(1-30)  (Fig.  1 A)  and extracellular 
staining  of its  fibromatous component  by  anti-CC(1-30) 
(Fig. 1 C) are clearly evident. Each of these two staining pat- 
terns is specific (Fig. 1, B and D) since staining was greatly 
reduced if the antibody preparations had been preincubated 
with TGF-/ffl-Sepharose  to remove TGF-/31-specific antibod- 
ies (Heine et al.,  1987).  Staining was also greatly reduced 
if the primary antibody was normal rabbit IgG (data not 
shown). 
This differential localization of TGF-/3 was consistently 
seen in a variety of murine and human cells and tissues, as 
shown in Fig. 2. Thus, Ha-ras-transformed NIH-3T3 cells, 
which produce large amounts of TGF-~I  (Anzano et al., 
1985; Jakowlew et al., 1987), are stained by anti-LC(1-30) 
but not by anti-CC(1-30) (Fig. 2, A and B). Tumors raised 
in nude mice from these cells (as well as from PC3 human 
prostatic carcinoma cells and from A549 human lung carci- 
noma cells), all showed intracellular staining by anti-LC(1- 
30),  as shown in Fig.  2  C  for the PC3  tumor.  However, 
anti-CC(1-30) stains only the tumor stroma (Fig. 2 D). Im- 
munohistochemical analysis of various organs in the  15-d 
mouse embryo further demonstrated this differential stain- 
ing;  Fig.  2  (E-H) shows peroxidase-stained sections of a 
mouse embryo foot and vertebra,  respectively. Subdermal 
mesenchyme of the foot was stained by anti-CC(1-30), while 
only chondrocytes in cartilage of the developing bones were 
stained by anti-LC(1-30). In vertebrae where ossification is 
just  beginning,  anti-CC(1-30)  stained  calcifying  matrix 
around  chondrocytes,  while  anti-LC(1-30)  again  stained 
proliferating chondrocytes. 
This differential staining has also been consistently found 
in a number of adult and neonatal mouse organs (Thompson 
et al.,  1989),  as well as in sections of human colon carci- 
nomas (see below). Furthermore, in human and rat arthritic 
joints anti-LC(1-30) stains mononuclear cells and synovial 
cells, while anti-CC(1-30) stains extracellularly around the 
synovial cells (Lafyatis et al.,  1988). 
Anti-LC(1-30) and Anti-CC(1-30) Recognize 
Different Epitopes of the TGF-~I Molecule 
To determine the basis of the different staining patterns, we 
have measured the reactivities of anti-LC(1-30) and anti- 
CC(1-30) in several  immunoassays. Each antibody was as- 
sayed for its ability to immunoprecipitate '25I-TGF-/31. The 
EDs0 for anti-LC(1-30) was 1:250 with a maximum immu- 
noprecipitation of 75 % of the '25I-TGF-~l added, while the 
corresponding  values  for  anti-CC(1-30)  were  1:100 and 
35 %, respectively.  While these differences in immunopre- 
cipitation of '25I-TGF-~  from solution may reflect varying 
concentrations of TGF-/3-specific  antibodies in the two anti- 
sera,  differences in the accessibility of the epitope recog- 
nized by each of these antibodies in native TGF-/31 may also 
contribute. 
To investigate this possibility, the antibodies were tested 
for their reactivities with various peptides in an ELISA assay 
(Table I). When tested against peptide LC(1-30), the antisera 
generated against this peptide, anti-LC(1-30), gave an EDso 
of 1:4,000, while anti-CC(1-30), which was generated to the 
other synthetic preparation of peptide, gave an EDs0 of only 
1:200  against  the  peptide  LC(1-30).  EUingsworth  et  al. 
(1986) have reported an EDs0 of 1:10,000 for anti-CC(1-30) 
when  tested  against  the  peptide  to  which  it  was  raised 
(CC[1-30]), but none of the peptide from this synthesis re- 
The Journal  of Cell Biology,  Volume 108, 1989  654 Figure 1. Demonstration of staining specificity.  Bovine fibropapillomas  were stained by (A) anti-LC(1-30) preincubated with Sepharose- 
control resin; (B) anti-LC(l-30) preincubated with TGF-fll coupled to Sepharose; (C) anti-CC(1-30) preincubated with Sepharose-control 
resin; (D) anti-CC(1-30) preincubated with TGF-~I coupled with Sepharose. Antisera were prepared as described in Heine et al. (1987). 
Anti-LC(l-30) stains epithelium (e), while anti-CC(l-30) stains the fibromatous  component (f) of  the fibropapilloma.  In each case, staining 
was greatly reduced when antibody was preincubated with TGF-t31-Sepharose. Sections were stained with peroxidase and counterstained 
with Giemsa and May-Grunwald stains. Bar, 100 ~m. 
mained for testing with anti-LC(1-30). These data suggest 
that the peptides generated by the two syntheses are in differ- 
ent  conformations and  that  the  two  antibodies  recognize 
different epitopes of the peptides. In order to test this possi- 
bility, the two antisera were tested against shorter peptides 
corresponding to residues 1-10, 11-20, and 21-30 of TGF-fll. 
Both  antisera  showed  reactivity  with  the  amino-terminal 
peptide 1-10, neither showed reactivity with the middle pep- 
tide 11-20, while only anti-LC(1-30) showed reactivity with 
peptide 21-30.  It should be noted that anti-CC(1-30)  had 
greater reactivity with TGF-fll than it did with any of the 
short peptides, suggesting that the epitope of TGF-fll recog- 
nized by anti-CC(l-30) is a discontinuous one that does not 
exist in the shorter peptides.  Furthermore, anti-LC(1-30) 
also had significant reactivity to the peptide corresponding 
to the amino-terminal 30 amino acids of TGF-/~2; this proba- 
bly results from the ability ofanti-LC(1-30) to react with the 
peptide corresponding to residues 21-30  of TGF-/~I, since 
this region is highly conserved between TGF-fll and 2, as 
well as in the deduced sequences  of the newly described 
TGF-/~3 and 4  (Jakowlew et al.,  1988a,b; ten Dijke et al., 
1988). Thus, it must be considered that under fixation condi- 
tions  leading to  exposure  of this  epitope,  anti-LC(1-30) 
might detect TGF-/32, 3, or 4, as well as TGF-fll, in immuno- 
histochemical localizations. This cross-reactivity is not seen 
in Western blots however, where both antibodies detect 10 ng 
of TGF-fll, but do not detect 100 ng of TGF-~2. 
Anti-CC(1-30) May Recognize TGF-B  Associated with 
Extracellular Matrix 
Since the two antibodies seem to recognize different epitopes 
of TGF-/~I, we conducted additional immunohistochemical 
studies to investigate the differences in the two forms of  TGF- 
/~ detected by these antibodies. Mesenchymal areas stained 
with anti-CC(1-30) are rich in extracellular matrix proteins 
such as collagen and fibronectin. In fibromatous areas of the 
bovine fibropapilloma,  the staining pattern of anti-CC(1- 
30)  is  generally restricted to areas  which also  stain with 
a  trichrome stain for collagen.  However,  while trichrome 
staining for collagen is uniform throughout the fibromatous 
area (data not shown), staining with anti-CC(1-30) is local- 
ized to fibromatous areas near the epithelium (Fig. 1 C). An 
analogous situation was found in human colon carcinomas 
(Fig. 3). Thus, antifibronectin antibody (Fig. 3 B) gave uni- 
form extracellular staining throughout tumor stroma, while 
staining by anti-CC(1-30) was localized (Fig. 3 A) to stromal 
areas near epithelial cells, which are stained by anti-LC(1- 
30)  (see Fig. 4). 
lntracellular Localization of TGF-/~ 
with Anti-LC(1-30) May Represent Sites 
of TGF-~ Synthesis 
Three other antibodies raised to TGF-/~I peptides showed in- 
Flanders et al. TGF-B  lmmunohistochemistry  655 Figure 2.  Differential  staining  patterns  with anti-LC(l-30) and anti-CC(l-30).  (A and B) Sections  of pellets  of Ha-ms NIH-3T3 cells; 
anti-LC(1-30) (A) stains cell cytoplasm and anti-CC(1-30) (B) gives no staining.  (C and D) Tumors raised  in nude mice after injection 
of PC-3 cells; anti-LC(1-30) (C) stains intracellularly,  while anti-CC(l-30) (D) stains stroma.  (E and F) Developing foot of a 15-d mouse 
embryo; chondrocytes (c) stained by anti-LC(1-30) (E) and mesenchyme (m) stained by anti-CC(1-30) (F). (G and H) 15-d mouse embryo 
vertebra;  proliferating chondrocytes (pc) stained by anti-LC(1-30) (G), or calcifying matrix (cc) stained by anti-CC(1-30) (H). Peroxidase, 
with Geimsa and May-Grunwald counterstain.  Bars: (A and B)  10/~m;  (C-H) 100 #m. 
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ED~o (antiserum dilution) 
Antigen  Anti-LC(I-30)  Anti-CC(l-30) 
Peptide  1-10  1:1,350  1:150 
11-20  0  0 
21-30  1:300  0 
1-30 (LC)  1:4,000  1:200 
1-30 (TGF-~2)  1:600  1  : 100 
TGF-~ 1  1  : 1,000  1:450 
TGF-~2  0  0 
* Antigens were plated in microtiter plates and tested with serial  dilutions of 
lgG fractions of each antiserum, beginning with equal amounts of lgG. Values 
reported are the dilutions which gave a half-maximal response. 
tracellular staining patterns  similar to those obtained with 
anti-LC(1-30).  The first antibody was  raised to a  peptide 
corresponding to amino acids 50-75 of mature human TGF- 
El, while the second antibody was generated to amino acids 
266-278 of the human TGF-/51 precursor. Like anti-LC(1- 
30), both of these antibodies showed intracellular TGF-/3 lo- 
calization  in  A549  cells  grown  in  culture,  as  well  as  in 
tumors raised in nude mice from PC3 cells. Fig. 4 shows an 
example of this colocalization of staining in the epithelium 
of human colon carcinomas. The staining obtained with anti- 
P(50-75), raised to a second epitope of mature TGF-B1, pro- 
vides  further  evidence  that  the  intracellular  staining  is 
specific for TGF-/31. Specificity was  further shown by the 
reduction in staining which occurred when this antibody was 
removed by preincubation with TGF-~l-Sepharose (data not 
shown). A third antibody raised against amino acids 46-56 
of the TGF-B1 precursor showed the same localization to epi- 
thelial cells of the bovine fibropapillomas as did anti-LC(1- 
30) (data not shown). 
The  staining  of cells  with  the  antibodies  raised  to  the 
precursor peptides indicates that these cells may be sites of 
TGF-B synthesis.  Production of mature TGF-~I occurs by 
synthesis of  the entire TGF-~I precursor molecule, dimeriza- 
tion and formation of the appropriate disulfide bonds, pro- 
teolytic cleavage of the mature TGF-/31 molecule from the 
precursor sequence, and association with a binding protein 
to generate latent TGF-B (Miyazono et al.,  1988;  Wakefield 
et al., 1988). A punctate pattern of intracellular staining was 
especially apparent in A549 cells (Fig.  5) with both anti- 
LC(1-30) and anti-pre(266-278). Furthermore, two recom- 
binant Chinese hamster ovary (CHO) cell lines expressing 
either low or high amounts of TGF-/3 showed significantly 
more staining  with both anti-LC(1-30) and  anti-pre(266- 
278) in the high expressing cells than in the low expressing 
cells, again suggesting that anti-LC(1-30) staining correlated 
with TGF-~ biosynthesis (data not shown). 
Discussion 
We have found marked differences in the histochemical lo- 
calization  of TGF-/3,  using  two  antibodies  raised  to  two 
different synthetic preparations of the same peptide sequence 
corresponding to the first 30 amino acids of TGF-~I. The 
amino-terminal 30 amino acids of TGF-~I contain three cys- 
teine residues; since both peptides were synthesized with un- 
protected cysteines, it is likely that different chemical treat- 
Figure 3.  Comparison of staining by anti-CC(1-30)  and by anti- 
fibronectin  antibody. Human  colon  carcinoma  stained  by  (A) 
anti-CC(1-30), (B) anti-human fibronectin, and (C) normal rabbit 
serum IgG. While staining by antifibronectin is uniform throughout 
the tumor  stroma,  staining by anti-CC(1-30)  is localized in the 
stroma near the tumor epithelium (e). Sections were stained with 
glucose oxidase (pink reaction product) and counterstained with 
methyl green. Bar, 100 #m. 
ments  of the  peptide  while  on  the  resin  or  while  being 
removed from the resin have resulted in alternate folding pat- 
terns of the peptide. Since antigenic determinants can be as 
few as 5-10 amino acids (Tanaka et al.,  1985;  Dyrberg and 
Oldstone,  1986;  Van Regenmortel,  1987), it is conceivable 
that antibodies raised against the two peptides were gener- 
ated against unique epitopes of the TGF-/31 molecule. Data 
presented here and by Ellingsworth et al.  (1986) show that 
both antibodies against P(1-30) recognize TGF-~I in Western 
blots, RIA, and ELISA systems. However, our results (Table 
I) suggest that each antibody recognizes a different epitope 
Flanders et al.  TGF-~  lmmunohistochemistry  657 Figure  4.  Comparison of intracellular staining by anti-LC(1-30) 
and  other  peptide antibodies.  Human  colon  carcinomas were 
stained by (A) anti-LC(1-30), (B) anti-P(50-75) raised to a peptide 
corresponding to amino acids 50-75 of human mature TGF-B1, and 
(C) anti-pre(266-278) raised to a peptide corresponding to amino 
acids 266-278 of the human TGF-BI precursor. All antibodies stain 
tumor epithelium (e). Peroxidase, with methyl green counterstain. 
Bar, 100 t~m. 
of the  1-30  region of TGF-~I,  since  in  an  ELISA assay 
anti-LC(1-30) showed relatively strong reactivity to peptides 
corresponding to amino acids  1-10 and 21-30  of TGF-/Yl, 
while anti-CC(1-30) exhibited greater reactivity to TGF-~I 
than to any of the 10-amino acid peptides. This suggests that 
the epitope anti-CC(1-30) recognizes most strongly is made 
up of noncontinuous amino acids (Barlow et al.,  1986) that 
are only brought together correctly in TGF-BI  or P(1-30). 
The intracellular localization of immunoreactive TGF-/31 
by anti-LC(1-30) was also seen with anti-P(50-75), as well 
as with two different antibodies raised to the precursor se- 
quences not found in mature TGF-/~, anti-pre(46-56)  and 
anti-pre(266-278). Transformed cells known to produce rel- 
atively large amounts of TGF-~I are stained particularly well 
by these antibodies, as are recombinant CHO cells express- 
ing high levels of TGF-B1. Since the precursor remainder is 
lost from TGF-/3 upon activation, it is unlikely that the stain- 
ing pattern seen with anti-pre(266-278)  would result from 
endocytosis of TGF-~ after receptor binding; rather, the data 
suggest that cells which are stained by these antibodies are 
sites of TGF-~I synthesis. 
The  typical mutually exclusive staining of intraceUular 
TGF-B1 by anti-LC(1-30) and extracellular TGF-B1 by anti- 
CC(1-30) suggests a possible conformational change in TGF- 
upon secretion. Since little is known about the processing, 
secretion, and activation of TGF-B, the exact nature of this 
conformational change is not known. The intraceUular form 
of TGF-B recognized by anti-LC(1-30) may be the unpro- 
cessed precursor form or TGF-B that has been proteolyti- 
cally cleaved from its precursor, but still associated with the 
precursor remainder, as is known to occur in latent TGF-B 
(Miyazono et al.,  1988;  Wakefield et al.,  1988).  Secretion 
may change the spatial relationship of TGF-B with other pro- 
teins in the latent TGF-/~ complex and mask the epitope rec- 
ognized by anti-LC(1-30) while exposing the epitope recog- 
nized by anti-CC(1-30). 
Anti-CC(1-30), anticollagen, and antifibronectin antibod- 
ies all stain extracellular matrix. However, in contrast to the 
uniformly distributed staining of matrix found with anticol- 
lagen and antifibronectin antibodies, the extracellular stain- 
ing by anti-CC(1-30) is localized near cells which show in- 
tracellular  staining  by  anti-LC(1-30).  This  is  especially 
striking in human colon carcinomas, in which antifibronec- 
tin antibody gives uniform staining throughout the stroma, 
while anti-CC(1-30) shows staining of the stroma only near 
epithelial cells that stain positive for TGF-B with anti-LC(1- 
30) (Fig. 4). This presence of TGF-/3 in the stroma may be 
partially responsible for the desmoplastic response associ- 
ated with invasive carcinomas. Similar variations in the pat- 
terns of staining by anti-CC(1-30), anti-LC(1-30), antifibro- 
nectin, and anticollagen antibodies have also recently been 
found in the developing mouse lung (Heine, U.,  personal 
communication). TGF-~ has been shown to copurify with 
fibronectin under  neutral  conditions (Fava  and  McClure, 
1987); whether the association of TGF-B with fibronectin in 
vivo is the result of specific binding of either active or latent 
TGF-/$1 to fibronectin, or it is the result of a nonspecific as- 
sociation of TGF-BI with fibronectin and possibly with other 
matrix proteins, remains to be determined. 
The predominantly extracellular staining pattern reported 
here for anti-CC(1-30) has been reported previously in the 
mouse embryo by Heine et al. (1987), who found widespread 
and abundant extracellular TGF-B in many mesenchymal tis- 
sues, although some occasional intracellular localization of 
TGF-B with anti-CC(1-30) was found in specialized cells of 
mesenchymal origin, such as osteoblasts and chondrocytes. 
With the new anti-LC(1-30) that we have described here, we 
now have a new tool for further investigation of the spatial 
and temporal localization of TGF-B1 in the mouse embryo. 
We have recently found that anti-LC(1-30) stains many epi- 
thelial cells of the embryo, with intracellular mesenchymal 
staining occurring to a lesser degree (Flanders, K., unpub- 
lished observations).  Interestingly, in situ hybridization of 
The Journal of Cell Biology, Volume  108, 1989  658 Figure 5. Staining of sections of pellets of A549 cells by anti-LC(1-30)  and anti-pre(266-278).  Sections were stained by (A) anti-LC(1-30), 
(B) anti-LC(l-30) incubated with a 20-fold molar excess of peptide LC(1-30) over IgG, (C) anti-pre(266-278),  and (D) anti-pre(266-278) 
preincubated with a 20-fold molar excess  of peptide pre(266-278)  over IgG. Both antibodies show punctate cytoplasmic staining that is 
abolished when antibody is preincubated with appropriate peptide. Peroxidase, with methyl green counterstain. Bar, 100/xm. 
TGF-/~I in the mouse embryo indicates that TGF-/31 mRNA 
is present in both epithelial and mesenchymal cells (Lehnert 
and  Akhurst,  1988),  similar  to the localization  seen  with 
anti-LC(1-30). 
In conclusion, it is clear that the combined use of anti- 
LC(1-30) and anti-CC(1-30)  antibodies will be a  valuable 
tool for investigating the role of TGF-/3 in reciprocal relation- 
ships between epithelium and mesenchyme in many physio- 
logical and pathological states, such as embryogenesis, mor- 
phogenesis,  repair  of tissue  damage,  and  carcinogenesis. 
The  additional use  of in  situ  hybridization techniques  for 
TGF-~,  which have been  described  recently  (Lehnert  and 
Akhurst, 1988; Sandberg et al., 1988; Wilcox and Derynck, 
1988)  combined with immunohistochemistry,  will  provide 
further important insights into the mechanism of TGF-/3 ac- 
tion. The present studies should also focus attention on the 
future importance of physicochemical studies on the struc- 
ture of the TGF-/~ molecule itself (including its latent form), 
since the ultimate understanding of the complex staining pat- 
terns reported here will rest on elucidation of the molecular 
structure of the actual epitopes that are stained by different 
antibodies. 
We thank  Dr.  Arthur Levinson for  CHO  cells  expressing  recombinant 
TGF-131,  and Larry Mullen for expert technical assistance. 
Received for publication 27 May  1988,  and in revised form 10 October 
1988. 
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